Abstract: Provided herein are methods of treatment of an individual having pain, e.g., neuropathic pain, comprising administering to the individual a therapeutically effective amount of tissue culture plastic adherent placental stem cells (PDAC™).
Abstract: In one embodiment, provided herein are cells, e.g., T cells expressing receptors that that cause a cell expressing the receptors to home to specific anatomical regions, e.g., the B cell zone of lymph nodes, the gastrointestinal tract, or the skin. Also provided herein is use of such cells, e.g., T lymphocytes, to treat diseases such as cancer.
Abstract: Provided herein are methods of treating a hematological disorder, a solid tumor, or an infectious disease in a subject in need thereof using natural killer cells in combination with a second agent, or using natural killer cells with genetic modifications for target specificity and/or homing specificity.
Type:
Application
Filed:
December 30, 2015
Publication date:
January 25, 2018
Applicant:
ANTHROGENESIS CORPORATION
Inventors:
Lin KANG, Xiaokui ZHANG, Jeffrey HARRIS, Vladimir JANKOVIC
Abstract: Provided herein are methods of producing natural killer (NK) cells using a three-stage expansion and differentiation method with media comprising stem cell mobilizing factors. Also provided herein are methods of suppressing tumor cell proliferation using the NK cells and the NK cell populations produced by the three-stage methods described herein, as well as methods of treating individuals having cancer or a viral infection, comprising administering the NK ce3lls and the NK cell populations produced by the three-stage methods described herein to an individual having the cancer or viral infection.
Type:
Application
Filed:
December 30, 2015
Publication date:
January 11, 2018
Applicant:
ANTHROGENESIS CORPORATION
Inventors:
Brian MURPHY, Vanessa VOSKINARIAN-BERSE, Andrea NORDBERG, Keith WILSON, Lin KANG
Abstract: Provided herein are methods for the isolation of platelets, for example, isolation of platelets from umbilical cord blood. In certain embodiments, presented herein are methods for preparation of platelet rich plasma. In one aspect, provided herein are methods for isolation of platelets from blood. In certain embodiments, presented herein are methods for isolation of platelets from cord blood, e.g., human cord blood. The isolated platelets can be used for a variety of applications, including, for example, methods of wound healing, organ repair and/or regeneration, and/or tissue repair and/or regeneration, in either autologous or allogenic settings.
Abstract: The present invention provides improved compositions and methods for the collection of stem cells from an organ, e.g., placenta. The invention provides a stem cell collection composition comprising an apoptosis inhibitor and, optionally, an enzyme such as a protease or mucolytic enzyme, vasodilator, necrosis inhibitor, oxygen-carrying perfluorocarbon, or an organ preserving compound. The invention provides methods of using the stem cell collection composition to collect stem cells and to preserve populations of stem cells.
Type:
Application
Filed:
July 28, 2017
Publication date:
November 16, 2017
Applicant:
Anthrogenesis Corporation
Inventors:
James W. Edinger, Mohammad Heidaran, Wolfgang Hofgartner
Abstract: Provided herein are methods of using tissue culture plastic-adherent placental cells, e.g. placental stem cells, in the treatment of diabetic foot ulcer (DFU).
Type:
Application
Filed:
September 25, 2015
Publication date:
October 12, 2017
Applicant:
Anthrogenesis Corporation
Inventors:
Steven A. FISCHKOFF, Denesh CHITKARA, Uri HERZBERG, Vladimir JANKOVIC
Abstract: The present invention provides compositions comprising human placental telopeptide collagen, methods of preparing the compositions, methods of their use and kits comprising the compositions. The compositions, kits and methods are useful, for example, for augmenting or replacing tissue of a mammal.
Type:
Grant
Filed:
February 26, 2013
Date of Patent:
September 26, 2017
Assignee:
Anthrogenesis Corporation
Inventors:
Mohit Bhatia, Chris Lugo, Qian Ye, James W. Edinger
Abstract: Provided are methods for quantifying and/or detecting sub-visible particulates in cell cultures. Specifically, the methods comprise a step of breaking down, e.g., lysing, cells in a cell culture. The methods can further comprising filtering the cell culture through a filter. Further provided are methods of quantifying sub-visible particulates that do not pass through the filter using a microscope.
Type:
Application
Filed:
September 11, 2015
Publication date:
September 21, 2017
Applicant:
ANTHROGENESIS CORPORATION
Inventors:
Lauren M. DEPALMA, Daniel DEWITT, Li REN
Abstract: Provided herein are placental perfusate, placental perfusate cells, placenta-derived intermediate natural killer cells, combined natural killer cells from placenta and umbilical cord blood, and combinations thereof. Also provided herein are compositions comprising the same, and methods of using placental perfusate, placental perfusate cells, placenta-derived intermediate natural killer cells, and combined natural killer cells and combinations thereof, to suppress the growth or proliferation of tumor cells, cancer cells, and the like, and to treat individuals having tumor cells. Also provided herein are methods of treating an individual having a tumor or graft-versus-host disease with placental perfusate, placental perfusate-derived cells, natural killer cells from placenta, e.g., from placental perfusate, and/or combined natural killer cells comprising natural killer cells from placenta, e.g., from placental perfusate, and umbilical cord blood.
Type:
Grant
Filed:
February 4, 2014
Date of Patent:
September 19, 2017
Assignee:
ANTHROGENESIS CORPORATION
Inventors:
Xiaokui Zhang, Robert J. Hariri, Vanessa Voskinarian-Berse, Lin Kang, Eric Law, Stewart Abbot
Abstract: Provided herein are compositions of placenta-derived adherent cell exosomes and methods of making and using the same. In one aspect, provided herein are compositions comprising exosomes produced by and/or derived from placental cells, e.g., placenta-derived adherent cells. In certain embodiments, the exosomes provided herein are produced by placenta-derived adherent cells that have been cultured in vitro for, e.g., 1, 2, 3, 4, 5, 6 or more passages.
Type:
Application
Filed:
October 8, 2015
Publication date:
September 7, 2017
Applicant:
Anthrogenesis Corporation
Inventors:
Eric LAW, Andrew MORSCHAUSER, Aleksandar FRANCKI, Jennifer PAREDES, Kathy E. KARASIEWICZ-MENDEZ, Allan REDUTA, Vladimir JANKOVIC, Ivana DJURETIC
Abstract: Provided herein are methods of producing erythrocytes from hematopoietic cells, particularly hematopoietic cells from placental perfusate in combination with hematopoietic cells from umbilical cord blood, wherein the method results in accelerated expansion and differentiation of the hematopoietic cells to more efficiently produce administrable erythrocytes. Further provided herein is a bioreactor in which hematopoietic cell expansion and differentiation takes place.
Type:
Application
Filed:
October 28, 2015
Publication date:
August 24, 2017
Applicant:
Anthrogenesis Corporation
Inventors:
Mohammad A. Heidaran, Xiaokui Zhang, Lin Kang, Andrew Zeitlin, Vanessa Voskinarian-Berse, Stewart Abbot
Abstract: The present invention provides compositions and methods of using placental stem cells that originate from a post-partum placenta with conventional cord blood compositions or other stem or progenitor cells. The placental stem cells can be used alone or in a mixture with other stem cell populations. In accordance with the present invention, the placental stem cells may be mixed with other stem cell populations, including but not limited to, umbilical cord blood, fetal and neonatal hematopoietic stem cells and progenitor cells, human stem cells and progenitor cells derived from bone marrow. The placental stem cells and the mixed populations of placental stem cells and stem cells have a multitude of uses and applications, including but not limited to, therapeutic uses for transplantation and treatment and prevention of disease, and diagnostic and research uses.
Abstract: The present invention provides improved compositions and methods for the collection of stem cells from an organ, e.g., placenta. The invention provides a stem cell collection composition comprising an apoptosis inhibitor and, optionally, an enzyme such as a protease or mucolytic enzyme, vasodilator, necrosis inhibitor, oxygen-carrying perfluorocarbon, or an organ preserving compound. The invention provides methods of using the stem cell collection composition to collect stem cells and to preserve populations of stem cells.
Type:
Grant
Filed:
July 29, 2010
Date of Patent:
August 8, 2017
Assignee:
Anthrogenesis Corporation
Inventors:
James W. Edinger, Mohammad Heidaran, Wolfgang Hofgartner
Abstract: Provided herein are organoids comprising decellularized placental vascular scaffold comprising, or consisting of, a decellularized placental vascular scaffold, and methods of making and using the same.
Type:
Application
Filed:
June 15, 2016
Publication date:
May 11, 2017
Applicant:
ANTHROGENESIS CORPORATION
Inventors:
Mohit B. Bhatia, Robert J. Hariri, Wolfgang Hofgartner, Jia-Lun Wang, Qian Ye
Abstract: The present invention provides compositions comprising human placental telopeptide collagen, methods of preparing the compositions, methods of their use and kits comprising the compositions. The compositions, kits and methods are useful, for example, for augmenting or replacing tissue of a mammal.
Type:
Application
Filed:
December 19, 2016
Publication date:
April 6, 2017
Applicant:
Anthrogenesis Corporation
Inventors:
Mohit B. Bhatia, Chris Lugo, Qian Ye, James W. Edinger
Abstract: A method of manufacturing a tissue matrix for implantation into a patient is disclosed. The method sets forth collecting embryonic stem cells from a placenta which has been treated to remove residual cord blood and seeding the collected stem cells onto or into a tissue matrix. The seeded tissue matrix is then implanted on or into a patient. The seeded tissue matrix made by the method of the present invention is also disclosed.
Abstract: The present invention provides improved compositions and methods for the collection of stem cells from an organ, e.g., placenta. The invention provides a stem cell collection composition comprising an apoptosis inhibitor and, optionally, an enzyme such as a protease or mucolytic enzyme, vasodilator, necrosis inhibitor, oxygen-carrying perfluorocarbon, or an organ preserving compound. The invention provides methods of using the stem cell collection composition to collect stem cells and to preserve populations of stem cells.
Type:
Grant
Filed:
December 28, 2006
Date of Patent:
March 21, 2017
Assignee:
Anthrogenesis Corporation
Inventors:
James W. Edinger, Mohammad Heidaran, Wolfgang Hofgartner
Abstract: Provided herein are methods of using adherent placental stem cells and placental stem cell populations, and methods of culturing, proliferating and expanding the same. Also provided herein are methods of differentiating the placental stem cells. Further provided herein are methods of using the placental stem cells to formulate implantable or injectable compositions suitable for administration to a subject. Still further provided herein are provides methods for treating bone defects with stem cells and compositions comprising stem cells.
Type:
Application
Filed:
April 7, 2016
Publication date:
March 2, 2017
Applicant:
Anthrogenesis Corporation
Inventors:
James W. Edinger, Robert J. Hariri, Jia-Lun Wang, Qian Ye, Kristen S. Labazzo, Marian Pereira, Sascha Dawn Abramson